TW202317178A - 因子ⅷ嵌合蛋白的配製品及其用途 - Google Patents

因子ⅷ嵌合蛋白的配製品及其用途 Download PDF

Info

Publication number
TW202317178A
TW202317178A TW111123492A TW111123492A TW202317178A TW 202317178 A TW202317178 A TW 202317178A TW 111123492 A TW111123492 A TW 111123492A TW 111123492 A TW111123492 A TW 111123492A TW 202317178 A TW202317178 A TW 202317178A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
arginine
polysorbate
histidine
sucrose
Prior art date
Application number
TW111123492A
Other languages
English (en)
Chinese (zh)
Inventor
泰勒 卡雷吉
藍道 穆爾丁
勞伯納 塔茲
堤莫席 麥可寇伊
Original Assignee
美商百歐維拉提夫治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百歐維拉提夫治療公司 filed Critical 美商百歐維拉提夫治療公司
Publication of TW202317178A publication Critical patent/TW202317178A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111123492A 2021-06-23 2022-06-23 因子ⅷ嵌合蛋白的配製品及其用途 TW202317178A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163214246P 2021-06-23 2021-06-23
US202163214245P 2021-06-23 2021-06-23
US63/214,246 2021-06-23
US63/214,245 2021-06-23
US202163214752P 2021-06-24 2021-06-24
US63/214,752 2021-06-24
US202163231909P 2021-08-11 2021-08-11
US63/231,909 2021-08-11

Publications (1)

Publication Number Publication Date
TW202317178A true TW202317178A (zh) 2023-05-01

Family

ID=82656587

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111123492A TW202317178A (zh) 2021-06-23 2022-06-23 因子ⅷ嵌合蛋白的配製品及其用途

Country Status (12)

Country Link
US (1) US20240287158A1 (enExample)
EP (1) EP4358938A1 (enExample)
JP (1) JP2024522855A (enExample)
KR (1) KR20240024949A (enExample)
AU (1) AU2022298798A1 (enExample)
BR (1) BR112023026782A2 (enExample)
CA (1) CA3220564A1 (enExample)
CO (1) CO2023017358A2 (enExample)
IL (1) IL309309A (enExample)
MX (1) MX2023015238A (enExample)
TW (1) TW202317178A (enExample)
WO (1) WO2022271962A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
EP4489771A2 (en) * 2022-03-08 2025-01-15 Bioverativ Therapeutics Inc. Methods of treating hemophilia a

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE198277T1 (de) * 1992-10-02 2001-01-15 Genetics Inst Zusammensetzung, welche den koagulationsfaktor viii beinhaltet; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator
EP2385825B1 (en) * 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
EA201691111A1 (ru) 2014-01-10 2017-01-30 Байоджен Ма Инк. Химерные белки фактора viii и их применение
KR102914074B1 (ko) 2018-05-18 2026-01-16 바이오버라티브 테라퓨틱스 인크. A형 혈우병의 치료 방법
AU2020298233A1 (en) * 2019-06-19 2022-01-20 Bioverativ Therapeutics Inc. Recombinant factor VIII-Fc for treating hemophilia and low bone mineral density
WO2021032646A1 (en) * 2019-08-16 2021-02-25 Octapharma Ag Stabilizing buffer for factor viii and vwf
EP4489771A2 (en) * 2022-03-08 2025-01-15 Bioverativ Therapeutics Inc. Methods of treating hemophilia a

Also Published As

Publication number Publication date
US20240287158A1 (en) 2024-08-29
CA3220564A1 (en) 2022-12-29
CO2023017358A2 (es) 2024-01-15
IL309309A (en) 2024-02-01
EP4358938A1 (en) 2024-05-01
JP2024522855A (ja) 2024-06-21
KR20240024949A (ko) 2024-02-26
BR112023026782A2 (pt) 2024-03-12
AU2022298798A1 (en) 2024-02-08
MX2023015238A (es) 2024-03-08
WO2022271962A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
US11510968B2 (en) Method for improving the stability of purified Factor VIII after reconstitution
EP3793588B1 (en) Methods of treating hemophilia a
JP6425674B2 (ja) 凍結乾燥した組換え型ｖｗｆ製剤
JP2011508742A (ja) 組換え型ｖｗｆ製剤
CN106659771B (zh) 修饰的von Willebrand因子
CN105392495A (zh) 具有xten的凝血酶可裂解连接子和其用途
JP2024522855A (ja) 第ｖｉｉｉ因子キメラタンパク質の製剤およびその使用
EP4415693B1 (en) Formulations of factor viii chimeric proteins and uses thereof
AU2020216976A1 (en) Methods of prophylactic treatment using recombinant VWF (rVWF)
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
BR112019003302A2 (pt) proteína de fusão fator viii de coagulação de sangue humano altamente glicosilada, e método de preparação e seu uso
AU2015258240A1 (en) Method of improving the stability of purified factor viii after reconstitution